Genmab Receivables 2019-2025 | GMAB

Genmab receivables for the quarter ending March 31, 2025 were $0.799B, a 17.28% increase year-over-year.

  • Genmab receivables for 2024 were $0.97B, a 35.07% increase from 2023.
  • Genmab receivables for 2023 were $0.718B, a 16.19% decline from 2022.
  • Genmab receivables for 2022 were $0.857B, a 58.54% increase from 2021.

Genmab Receivables 2019-2025 | GMAB

  • Genmab receivables for 2024 were $0.97B, a 35.07% increase from 2023.
  • Genmab receivables for 2023 were $0.718B, a 16.19% decline from 2022.
  • Genmab receivables for 2022 were $0.857B, a 58.54% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B
Bio-Rad Laboratories (BIO.B)$6.3B